Zusammenfassung für Investoren
SOMAÍ Pharmaceuticals, established in 2019, has swiftly emerged as a significant player in the medical cannabis industry, focusing on the development and distribution of cannabinoid-based drug formulations. The company’s journey began with a vision to revolutionize healthcare through innovative cannabis-based treatments. Emphasizing research and clinical trials, SOMAÍ has dedicated itself to advancing the medical applications of cannabinoids.
The financial trajectory of SOMAÍ Pharmaceuticals reflects a strong commitment to growth and innovation. The company had raised 22,3 mln EUR from several private investors and private equity firms. Also SOMAÍ successfully qualified for the grant of 2,1 mln EUR from the Portugal authority.
For more detailed information and investment opportunities, please read our equity research and reach out to us via hello@somaipharma.eu.
Equity Research